Replies to post #277505 on Amarin Corp Plc (AMRN)

[couldbebetter]

Zumantu, Another study showing that 4 grams of EPA ameliorates
systemic inflammation. (Not that we need any more proof!) I have
no doubt that Vascepa should be a solid candidate to treat the
residual inflammatory impact of COVID-19. (In July AMRN should
have more to report about concerning this area.) I sure would
like JT and Dr. Bhatt to be more aggressive (OK, I'll take even
a little aggressive, with regard to Vascepa and COVID-19.)

With a little luck maybe some BP will figure out that (at least in
Europe) Vascepa could be sold for CVD and for the treatment of
COVID-19 induced CVD. Certainly some BP has to be aware of this!
Right!?!?

[HinduKush]

GREAT therapeutic opportunity for Amarin :Known for a long time postpartum depression, deprssion related to menstrual disorders have all been documented to respond to EPA/DHA supplementation almost as long as its clinical use in Lipid disorders apparently.


Adams P.B., Lawson S., Sanigorski A., Sinclair A.J. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids. 1996;31:S157–S161.

A relationship between depression and the ratio of omega-3 and omega-6 fatty acid concentration of erythrocyte phospholipids and plasma was examined by Adams et al15 in 20 moderate to severe depressed patients. The ratio of erythrocyte arachidonic acid to EPA in a significant correlation with depression severity was observed. In addition, a significant negative correlation was observed between erythrocyte EPA and depression. The authors, however, concluded that these results cannot be explained simply by differences in the dietary intakes of EPA.